Hanmi Pharm Reports Q1 Operating Profit of 38.7 Billion KRW, Up 29.4% Year-on-Year

[Asia Economy Reporter Lee Gwan-joo] Hanmi Pharmaceutical announced on the 27th that it recorded provisional consolidated results for the first quarter with sales of 321.1 billion KRW, operating profit of 38.7 billion KRW, and net profit of 24.8 billion KRW.

Sales increased by 18.8% compared to the same period last year, while operating profit and net profit grew by 29.4% and 6.9%, respectively. The company invested 37.2 billion KRW, equivalent to 11.6% of sales, in research and development (R&D) to create future growth engines.

Hanmi Pharmaceutical stated that its improved and combination drugs developed with proprietary technology, such as the Amozantan family and Rosuzet, continued steady growth, and the strong performance of its local Chinese subsidiary, Beijing Hanmi Pharmaceutical, which has shown rapid growth since last year, was reflected.

Hanmi Pharmaceutical's first-quarter prescriptions outside hospitals recorded 194.3 billion KRW (based on UBIST), an 11.8% increase compared to the same period last year, maintaining its No. 1 position domestically. The combination drug for dyslipidemia treatment, Rosuzet, achieved prescription sales of 32.7 billion KRW, up 13.1% year-on-year, and the combination drug for hypertension treatment, the Amozantan family, grew by 5.8% to 31.9 billion KRW, leading the strong first-quarter performance.

Progress is also accelerating in global innovative drug development. Hanmi Pharmaceutical's first biologic drug, Rollontis, has entered the official review stage by the U.S. Food and Drug Administration (FDA), with final marketing approval expected in September this year. The FDA decision on the approval of the anticancer innovative drug Poziotinib is scheduled for November.

Beijing Hanmi Pharmaceutical, the local Chinese subsidiary, recorded consolidated sales of 94.8 billion KRW in the first quarter, a 29.1% increase compared to the previous year. Operating profit rose 32.8% to 25.5 billion KRW, and net profit increased 33.1% to 22.9 billion KRW.

Additionally, Hanmi Science, the holding company of the Hanmi Pharmaceutical Group, posted consolidated first-quarter sales of 252 billion KRW, up 17.1% year-on-year, and operating profit increased 43% to 19.6 billion KRW.

Wo Jong-su, CEO of Hanmi Pharmaceutical, said, “The ‘Korean-style R&D virtuous cycle management system,’ which progresses from first generics to improved and combination drugs and innovative drug development, has now firmly taken root. We will accelerate innovative drug development to advance Hanmi globally on the foundation of stable performance.”

This content was produced with the assistance of AI translation services.